Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
about
Oncolytic viruses as therapeutic cancer vaccinesPathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationOverlapping, additive and counterregulatory effects of type II and I interferons on myeloid dendritic cell functionsTherapeutic cancer vaccines and combination immunotherapies involving vaccinationLangerhans cells and T cells sense cell dysplasia in oral leukoplakias and oral squamous cell carcinomas--evidence for immunosurveillance.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcelluloIn vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imagingCytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response.Immunotherapy of cancer in 2012.Monocytes to functional dendritic cells is often a bridge too far for cancer therapy.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments.Exploiting dendritic cells in the development of cancer vaccines.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.Dendritic cell based vaccination strategy: an evolving paradigm.Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.Dendritic cell immunotherapy for brain tumors.Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.Further clinical advancement of dendritic cell vaccination against ovarian cancer
P2860
Q21245758-F6257EFF-EADF-4B8C-BBBB-445B922074A7Q26765345-CDD65464-F253-47A2-AA9C-2BB5D88E7224Q27014714-50173C3A-0A1B-446C-9632-850BE37D5686Q28397609-A9818006-BB22-4E54-A78E-AAE63280D4CBQ34216915-CD1C2FED-327A-43F2-9FE2-2849C75F7D60Q34292741-28441B06-89E2-488F-98CC-1CB70D579B86Q34666875-7E422EE0-0094-49E1-B974-CD63C7D7AD79Q34716748-1E362CDF-0350-4222-A3E7-B070E6442758Q35167582-359D4DAB-B5EB-41E2-8149-9AC0414D9D91Q36243536-7964B4E9-161A-4413-8201-A1F5240EC128Q36350299-BD1C7B3E-63CE-4ECD-81EE-2F604A1E206BQ36821243-DCF94E2F-5ECB-4FA0-8FCE-4037E7F2A635Q37211699-66FD0445-E622-4106-B1BA-82B5EFD78B2BQ37891886-3F008FEF-A60D-4EE2-878F-AFD8DFF95BE6Q38148774-D7485F02-82A9-4630-8684-7A1D36626424Q38261273-03D7AAC8-7D36-449A-8FF3-8221F268CC98Q38691953-9545EEB7-546A-4079-B9CA-6B83EF509F3DQ39123677-58803AC5-D6B5-4A0A-8BA2-E2F2F5305DB6Q40875816-B138DF77-D5C9-4B91-83E5-BD02DD8756DDQ41520681-418C6C9B-D9F3-4A6F-9BCF-94B84F8E1014Q45967667-D6191D57-2E11-411E-B288-7AA30F7A638DQ55003884-8F78ADAA-74B0-4858-825C-313787D82C0CQ57824330-403C6D67-86D8-4011-AE87-9D1E39A4A465
P2860
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@en
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@nl
type
label
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@en
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@nl
prefLabel
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@en
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@nl
P2860
P1476
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
@en
P2093
Hideho Okada
Pawel Kalinski
P2860
P304
P356
10.1016/J.SMIM.2010.03.002
P577
2010-04-20T00:00:00Z